Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Follistatin vs. Similar Peptides: Side Effect Comparison

Comparative side effect analysis between follistatin and related research peptides provides context for risk assessment, though direct head-to-head studies remain limited. The following table compares adverse event profiles across similar peptides: Follistatin

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Comparative side effect analysis between follistatin and related research peptides provides context for risk assessment, though direct head-to-head studies remain limited. The following table compares adverse event profiles across similar peptides:
  • Follistatin
  • TGF-β antagonist
  • Injection site reactions (15-25%)
  • <1%
  • Limited human data
  • Myostatin inhibitors
  • Myostatin blockade
  • Muscle pain (20-30%)
  • 1-2%
  • More muscle-specific effects
  • Activin inhibitors
  • Activin A/B blockade
  • Fatigue (25-35%)
  • 2-3%
  • Greater systemic effects
  • IGF-1
  • Growth factor agonist
  • Hypoglycemia (15-20%)
  • 2-5%
  • 3-5%
  • Metabolic complications
  • Follistatin demonstrates a relatively favorable side effect profile compared to direct myostatin inhibitors, which commonly produce muscle pain and stiffness in 20-30% of research subjects.[1] However, follistatin's limited human safety database makes definitive comparisons challenging.
  • Activin inhibitors show higher rates of systemic effects, particularly fatigue (25-35%) and gastrointestinal disturbances (8-15%), likely due to broader pathway inhibition compared to follistatin's more selective binding profile.[2] The serious adverse event rate for activin inhibitors (2-3%) exceeds that reported for follistatin, though this may reflect more extensive human exposure data rather than inherent safety differences.
  • IGF-1 therapy presents distinct risks including hypoglycemic episodes (15-20% of subjects) and potential for acromegalic features with long-term use.[3] Follistatin's mechanism avoids direct metabolic pathway activation, potentially reducing these specific risks while introducing different concerns related to immune modulation.